Linkedin
RLS logo_header
Linkedin

Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies

FUJIFILM Corporation and Taiho Pharmaceutical announced that they have entered into a strategic partnership agreement for the development of manufacturing technologies for next-generation antibody-drug conjugates. Under this partnership, the two companies will work to optimize manufacturing processes for ADC candidates being developed by Taiho Pharmaceutical using the AraLinQ™ technology of Araris Biotech AG, a subsidiary of Taiho Pharmaceutical. By combining Taiho Pharmaceutical’s expertise and capabilities in ADC drug discovery with Fujifilm’s process development and manufacturing technologies cultivated through its biologics CDMO* business, the companies aim to achieve stable production of high-quality ADCs and enhance their global competitiveness in the next-generation ADC field.

Read the full story on "Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies"

Share:

More News

Gotistobart Nearly Doubled Median OS versus SOC Chemo in Previously Treated Squamous NSCLC Patients

“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel

Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program

“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated

Zipalertinib + chemo Demonstrates 6-Month Median PFS Benefit in REZILIENT3 Ph 3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC

“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with

FDA clears IND application to initiate Ph 1 study for PRT13722 for HR+/HER2- breast cancer patients

“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines